Pee test could revolutionize HIV treatment adherence

NCT ID NCT06423612

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial tests whether a low-cost, point-of-care urine test can help people with HIV who are not virally suppressed stick to their antiretroviral therapy. Participants provide a urine sample that is immediately tested for the presence of the drug tenofovir. Based on the result, they receive enhanced counseling to improve adherence. The study aims to see if this real-time feedback leads to better viral suppression rates compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: point-of-care urine test to measure adherence to antiretroviral therapy, with enhanced counseling based on results
What this could lead to: If effective, this simple and cheap urine test could help more people with HIV achieve viral suppression, improving health and reducing transmission.
What could go wrong: This is a single trial in one region, and the test only measures recent adherence. It may not work for everyone or in different settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ART ADHERENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ART ADHERENCE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Desmond Tutu HIV Foundation
RECRUITING

East London, South Africa

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.